NCI-H69/CPR

96042328, human lung, Not specified

• UNSPSC-Code: 41106514

Eigenschaften

• product name: NCI-H69/CPR, 96042328
• Biologische Quelle: human lung
• Wachstumsmodus: Aggregates in suspension
• Karyotyp: Not specified
• Morphologie: Not specified
• Produkte: Not specified
• Rezeptoren: Not specified
• Methode(n): cell culture | mammalian: suitable
• Relevante Krankheit(en): cancer
• Versandbedingung: dry ice
• Lagertemp.: −196°C

Beschreibung

Ursprung der Zelllinie

Human small cell lung cancer, drug-resistant

Beschreibung der Zelllinie

NCI-H69/CPR is a drug resistant subline of NCI-H69 (Sigma Catalogue number. 91091802). Drug resistance was developed by addition of a stepwise increase in cisplatin to the growth medium of the parental line. The cell line exhibits a 5-fold resistance to cisplatin and is cross resistant to melphalan. A significant change in cellular glutathione content or sensitivity to cadmium chloride (as indicator of metallothionein content) was not detected, but changes in glutathione-S-transferase activity were seen. Cisplatin accumulation was unchanged compared with the parent line. It is recommended to culture the cells without drugs after resuscitation until the first passage.

Anwendung

Drug-resistance studies, small cell lung cancer

Nährmedium

RPMI 1640 + 2mM Glutamine + 0.4μg/ml cisplatin + 10% Foetal Bovine Serum (FBS).

Subkultur-Routine

Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO₂; 37ºC; resuscitate in drug-free medium until first passage.

Sonstige Hinweise

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.